ANCA Vasculitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight's, "ANCA Vasculitis Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ANCA Vasculitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in ANCA Vasculitis Research. Learn more about our innovative pipeline today! @ ANCA Vasculitis Pipeline Outlook [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the ANCA Vasculitis Pipeline Report

* June 2024:- Amgen- A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
* June 2024:- Alpine Immune Sciences Inc.- An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3). The goal of this clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis). or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis to determine if povetacicept is safe and potentially beneficial in treating these diseases.
* DelveInsight's ANCA Vasculitis pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for ANCA Vasculitis treatment.
* The leading ANCA Vasculitis Companies such as Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.
* Promising ANCA Vasculitis Therapies such as BDB-001 injection, Cyclophosphamide, Glucocorticoids, Avacopan, Iptacopan, NM8074, and others.

Stay informed about the cutting-edge advancements in ANCA Vasculitis Treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases care @ ANCA Vasculitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

ANCA Vasculitis Emerging Drugs Profile

* Abatacept: Bristol-Myers Squibb

Abatacept is a selective T-cell co-stimulation modulator. Abatacept binds to CD80 and CD86 receptors on antigen-presenting cells (APCs), which are essential for T-cell activation. This binding blocks the interaction between CD80/CD86 and CD28, thereby inhibiting the delivery of the second co-stimulatory signal required for optimal T-cell activation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ANCA Vasculitis.

* Sparsentan : Travere Therapeutics

Sparsentan is a dual endothelin and angiotensin II receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Sparsentan acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), which are involved in the pathogenesis of IgAN. It selectively blocks the action of endothelin-1 (ET-1) and angiotensin II (Ang II) at their respective receptors, thereby reducing proteinuria. The drug is currently in Phase II of clinical trial evaluation for the treatment of ANCA Associated Vasculitis.

Learn more about ANCA Vasculitis Drugs opportunities in our groundbreaking ANCA Vasculitis Research and development projects @ ANCA Vasculitis Unmet Needs [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

ANCA Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

ANCA Vasculitis Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Discover the latest advancements in ANCA Vasculitis Treatment by visiting our website. Stay informed about how we're transforming the future of cardiovascular disease @ ANCA Vasculitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the ANCA Vasculitis Pipeline Report

* Coverage- Global
* ANCA Vasculitis Companies- Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.
* ANCA Vasculitis Therapies- BDB-001 injection, Cyclophosphamide, Glucocorticoids, Avacopan, Iptacopan, NM8074, and others.
* ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of ANCA Vasculitis Pipeline on our website @ ANCA Vasculitis Drugs and Companies [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* ANCA Vasculitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* ANCA Vasculitis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Abatacept: Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Sparsentan: Travere Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* ANCA Vasculitis Key Companies
* ANCA Vasculitis Key Products
* ANCA Vasculitis- Unmet Needs
* ANCA Vasculitis- Market Drivers and Barriers
* ANCA Vasculitis- Future Perspectives and Conclusion
* ANCA Vasculitis Analyst Views
* ANCA Vasculitis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=anca-vasculitis-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/



This release was published on openPR.